Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
38.75
+0.26 (0.68%)
Feb 21, 2025, 4:00 PM EST - Market closed
Protagonist Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 434.43 | 60 | 26.58 | 27.36 | 28.63 | Upgrade
|
| Revenue Growth (YoY) | 624.05% | 125.73% | -2.84% | -4.44% | 12293.07% | Upgrade
|
| Gross Profit | 434.43 | 60 | 26.58 | 27.36 | 28.63 | Upgrade
|
| Selling, General & Admin | 43.46 | 33.49 | 31.74 | 27.2 | 18.64 | Upgrade
|
| Research & Development | 138.13 | 120.16 | 126.22 | 126.01 | 74.51 | Upgrade
|
| Operating Expenses | 181.59 | 153.65 | 157.95 | 153.2 | 93.14 | Upgrade
|
| Operating Income | 252.84 | -93.65 | -131.37 | -125.85 | -64.52 | Upgrade
|
| Interest Expense | - | - | - | - | -0.6 | Upgrade
|
| Interest & Investment Income | 26.32 | 14.9 | 4.06 | 0.44 | 0.9 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.2 | -0.08 | -0.15 | -0.05 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.25 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 279.41 | -78.96 | -127.39 | -125.55 | -64.26 | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.59 | Upgrade
|
| Pretax Income | 279.41 | -78.96 | -127.39 | -125.55 | -64.85 | Upgrade
|
| Income Tax Expense | 4.22 | - | - | - | 1.31 | Upgrade
|
| Net Income | 275.19 | -78.96 | -127.39 | -125.55 | -66.15 | Upgrade
|
| Net Income to Common | 275.19 | -78.96 | -127.39 | -125.55 | -66.15 | Upgrade
|
| Shares Outstanding (Basic) | 62 | 57 | 49 | 46 | 34 | Upgrade
|
| Shares Outstanding (Diluted) | 65 | 57 | 49 | 46 | 34 | Upgrade
|
| Shares Change (YoY) | 14.65% | 15.74% | 5.87% | 34.67% | 32.84% | Upgrade
|
| EPS (Basic) | 4.47 | -1.39 | -2.60 | -2.71 | -1.92 | Upgrade
|
| EPS (Diluted) | 4.23 | -1.39 | -2.60 | -2.71 | -1.92 | Upgrade
|
| Free Cash Flow | - | -70.85 | -108.93 | -108.97 | -72.96 | Upgrade
|
| Free Cash Flow Per Share | - | -1.25 | -2.22 | -2.35 | -2.12 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | 58.20% | -156.09% | -494.24% | -460.01% | -225.36% | Upgrade
|
| Profit Margin | 63.34% | -131.59% | -479.26% | -458.94% | -231.07% | Upgrade
|
| Free Cash Flow Margin | - | -118.08% | -409.81% | -398.31% | -254.84% | Upgrade
|
| EBITDA | 253.79 | -92.68 | -130.34 | -125.03 | -63.57 | Upgrade
|
| EBITDA Margin | 58.42% | -154.46% | - | - | -222.05% | Upgrade
|
| D&A For EBITDA | 0.94 | 0.98 | 1.03 | 0.81 | 0.95 | Upgrade
|
| EBIT | 252.84 | -93.65 | -131.37 | -125.85 | -64.52 | Upgrade
|
| EBIT Margin | 58.20% | -156.09% | - | - | -225.36% | Upgrade
|
| Effective Tax Rate | 1.51% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.